^
Association details:
| Biomarker: | CD74-NRG1 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
Published date:
02/08/2022
Excerpt:
CONTRADICTING EVIDENCE: We investigated zenocutuzumab (Zeno, MCLA-128), an ADCC-enhanced anti-HER2xHER3 bispecific antibody, in NRG1 fusion-positive...A CD74-NRG1-positive NSCLC patient who had progressed on six prior lines of systemic therapy including afatinib responded rapidly to treatment with a partial response. Targeting HER2 and HER3 simultaneously with Zeno is a novel therapeutic paradigm for patients with NRG1 fusion-positive cancers.
DOI:
https://doi.org/10.1158/2159-8290.CD-21-1119
Source:
Title:
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Published date:
11/24/2019
Excerpt:
Of this entire cohort, only one (0.04%) patient was identified with a CD74-NRG1 fusion….The patient was considered to have a partial response (PR) to afatinib, and he was alive up to now.
